Tetracycline
| Evidence Level: L4 | Predicted Indications: 4 |
Table of Contents
Tetracycline: From Bacterial Infections to Punctate Epithelial Keratoconjunctivitis
One-Sentence Summary
Tetracycline is a classic broad-spectrum antibiotic, long used to treat bacterial infections including Chlamydia trachomatis-related disease. The TxGNN model predicts it may be effective for Punctate Epithelial Keratoconjunctivitis, but this direction is currently supported by only 0 clinical trials and 1 case report (published in 1992) — very early-stage, exploratory evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections, broad-spectrum antibacterial (specific approved indication text not available in this evidence pack) |
| Predicted New Indication | Punctate Epithelial Keratoconjunctivitis |
| TxGNN Prediction Score | 99.58% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Tetracycline belongs to the tetracycline class of broad-spectrum antibiotics, and its efficacy against bacterial infections — including Chlamydia trachomatis — is well established. Mechanistically, this may extend to punctate epithelial keratoconjunctivitis, since this corneal condition is a recognized sequela of chlamydial follicular conjunctivitis.
The underlying rationale is that tetracyclines are a classic first-line therapy for chlamydial infections, and trachoma/chlamydial conjunctivitis is one of tetracycline’s textbook indications. Punctate epithelial keratitis frequently arises as a residual inflammatory lesion after the pathogen has already been cleared by antibiotic treatment — meaning the pharmacological link exists, but points to prevention of a downstream complication rather than direct treatment of an active, drug-responsive disease process.
Importantly, the only literature reference for this candidate is a single 1992 case report of two patients whose chlamydial follicular conjunctivitis resolved after oral tetracycline or doxycycline, but who subsequently developed persistent punctate keratitis. This report demonstrates that the keratitis occurred despite — not because of — successful antibiotic treatment, and does not provide evidence that tetracycline itself treats or prevents this residual corneal lesion. The mechanistic plausibility is real, but the clinical evidence supporting a treatment effect is essentially absent.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1424659 | 1992 | Case report | Cornea | Two patients with chlamydial follicular conjunctivitis, treated with oral tetracycline or doxycycline, had resolution of follicles but subsequently developed persistent bilateral punctate epithelial keratitis with fluorescein-staining lesions; one case had associated anterior stromal edema. Illustrates keratitis as a post-treatment sequela rather than a treatable target of tetracycline. |
India Market Information
Currently no market authorization records in India (0 registrations; product not marketed).
Safety Considerations
- Drug Interactions: A total of 308 documented interactions were identified. Notable Major-level interactions include Isotretinoin, Acitretin, and Aminolevulinic acid (photosensitization/retinoid-related risk). Several Moderate-level interactions involve antacid/mineral-containing agents (e.g., aluminum hydroxide, bismuth subcitrate) and other antibiotics (amoxicillin, ampicillin) due to chelation/absorption effects. Given the large number of interactions (308), full screening against a patient’s concurrent medication list is recommended before use.
Conclusion and Next Steps
Decision: Hold
Rationale: The only literature support for this predicted indication is a single 30-year-old case report that documents keratitis occurring after successful antibiotic treatment, not a therapeutic effect of tetracycline on the condition itself; combined with zero clinical trials and an L4/S1 evidence rating, the evidence base is insufficient to justify active development.
To proceed, the following is needed:
- TFDA/regulatory label warnings and contraindications (currently a blocking data gap — DG001)
- Confirmed mechanism of action and original approved indication text for Tetracycline (currently a data gap — DG002)
- Prospective or comparative studies directly evaluating tetracycline (not just doxycycline, its analog) for treatment or prevention of punctate epithelial keratoconjunctivitis
- Route of administration compatibility assessment (ophthalmic vs. systemic) — currently marked “pending” in the evidence pack
- Note: a related candidate, chronic rhinosinusitis (rank 3, L2/S2), has substantially stronger evidence (multiple RCTs and a systematic review/meta-analysis) but is based almost entirely on doxycycline, not tetracycline itself; if this program is pursued, that indication with an explicit tetracycline-vs-doxycycline extrapolation assessment may be a more productive next step than punctate keratoconjunctivitis.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.